Ali Md Ashraf, Wahed Mir Imam Ibne, Khatune Naznin Ara, Rahman Bytul Mokaddesur, Barman Ranjan Kumar, Islam Md Rafiqul
Department of Pharmaceutical Engineering & Drug Delivery Science, Graduate School of Integrated Pharmaceutical & Nutritional Sciences, University of Shizuoka, Shizuoka, 422-8526, Japan.
Department of Pharmacy, Mawlana Bhashani Science and Technology University, Tangail, 1902, Bangladesh.
BMC Complement Altern Med. 2015 Apr 29;15:138. doi: 10.1186/s12906-015-0662-z.
Diabetes mellitus is a global health problem and constantly increasing day by day. The number of diabetic people in world is expected to rise to 366 million in 2030. The available drugs for diabetes, insulin or oral hypoglycemic agents have one or more side effects and search for new antidiabetic drugs with minimal or no side effects from medicinal plants is a challenging for us. The present study was undertaken to investigate the antidiabetic and antioxidant activity of Semecarpus anacardium (Linn.) (abbreviated as SF).
The antidiabetic activity was determined by using alloxan-induced diabetic rats. After 15 days of treatment, serum biochemical parameters such as TC, TG, LDL, HDL, SGOT and SGPT were estimated. The survival rate, body weight, organ weight, liver glycogen and blood parameters (RBC and Hb) were also measured. The antioxidant activity was measured by DPPH free radical scavenging assay. Phytochemical screening, total phenolic and total flavonoid content were determined by using standard methods.
The results showed that the survival rate was 100% in rats of Group SA 400. The effect of extract on blood glucose level in Groups SA 100, SA 200 and SA 400 were dose-dependent throughout the treatment period. No significant changes in organ weight to body weight ratio were observed, liver weights significantly improved in Groups SA 200 and SA 400. The bark extract exhibited significant (p < 0.05) anti-diabetic activity with lowering TC, TG, LDL level dose-dependently and protected liver which may be partially explained by attenuation of SGOT and SGPT levels and increases liver glycogen. The percentage of Hb and RBC counts were negatively correlated with the doses of extracts. In DPPH scavenging assay, IC50 values of SA extract and ascorbic acid were found 72.24 μg/ml and 17.81 μg/ml, respectively. Phytochemical screening showed the presence of steroids, triterpenoids, flavonoids, glycosides, saponins, and tannins that were contribute to biological activity.
These results indicated that stem barks of S. anacardium possess strong anti-diabetic and antioxidant potentials and support traditional medicinal use for the treatment of diabetes mellitus and good source for natural antioxidants.
糖尿病是一个全球性的健康问题,且日益严重。预计到2030年,全球糖尿病患者人数将增至3.66亿。现有的糖尿病治疗药物,如胰岛素或口服降糖药,都有一个或多个副作用,因此从药用植物中寻找副作用最小或无副作用的新型抗糖尿病药物对我们来说是一项挑战。本研究旨在调查印度没药(Semecarpus anacardium (Linn.),简称SF)的抗糖尿病和抗氧化活性。
使用四氧嘧啶诱导的糖尿病大鼠来测定抗糖尿病活性。治疗15天后,评估血清生化参数,如总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、谷草转氨酶(SGOT)和谷丙转氨酶(SGPT)。还测量了存活率、体重、器官重量、肝糖原和血液参数(红细胞和血红蛋白)。通过DPPH自由基清除试验测量抗氧化活性。采用标准方法进行植物化学筛选、测定总酚和总黄酮含量。
结果显示,SA 400组大鼠的存活率为100%。在整个治疗期间,SA 100、SA 200和SA 400组提取物对血糖水平的影响呈剂量依赖性。未观察到器官重量与体重比有显著变化,SA 200和SA 400组的肝脏重量显著改善。树皮提取物表现出显著的(p < 0.05)抗糖尿病活性,可剂量依赖性地降低TC、TG、LDL水平,并保护肝脏,这可能部分归因于SGOT和SGPT水平的降低以及肝糖原增加。血红蛋白和红细胞计数百分比与提取物剂量呈负相关。在DPPH清除试验中,SA提取物和抗坏血酸的IC50值分别为72.24 μg/ml和17.81 μg/ml。植物化学筛选表明存在类固醇、三萜类、黄酮类、糖苷、皂苷和单宁,这些成分有助于其生物活性。
这些结果表明,印度没药的茎皮具有很强的抗糖尿病和抗氧化潜力,支持其在传统医学中用于治疗糖尿病,是天然抗氧化剂的良好来源。